

## Personal Information



## Saranya Chumsri

**Address:** Mayo Clinic, Jacksonville, USA

**Country:** USA

## Curriculum Vitae

Saranya Chumsri, M.D. is a medical oncologist who is specialized in breast cancer. Her research is focusing on several aspects of breast cancer, including genomics, immunologic, epigenetics, breast cancer stem cells, endocrine resistance, as well as an aggressive form of breast cancer lacking estrogen receptor, progesterone receptor, and HER2, termed triple negative breast cancer. Dr. Chumsri is a clinician scientist reviewer for the Breast Cancer Research Program for the Department of Defense Congressionally Directed Medical Research Programs, 2012-2015. She was also the Co-leader disease oriented group: breast cancer for the University of Chicago Phase II Consortium between 2011-2014

### Present Academic Rank and Position

- Senior Associate Consultant - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida 08/2014 – Present
- Associate Professor of Medicine - Mayo Clinic College of Medicine and Science 07/2017 – Present

### Education

- Chulalongkorn University, Bangkok, Thailand - MD 1999
- Albert Einstein Medical Center, Philadelphia, Pennsylvania - Resident, Internal Medicine 2002 – 2005
- University of Maryland Medical Center, Baltimore, Maryland - Fellow, Hematology/Oncology 2005 – 2008

### Certification

#### Board Certifications

- American Board of Hematology  
Diplomate 2008 – 2018
- American Board of Internal Medicine (ABIM)  
Medical Oncology 2005 – 2015
- American Board of Oncology  
Diplomate 2008 – 2018

## Honors and Awards

- Merit Award from Thai Science and Technology Association - Thai Science and Technology Association, Bangkok, Thailand Under The Royal Patronage of His Majesty the King 1993
- Talented Student who created reputation for the country - Thai National Children's Day Committee, Bangkok, Thailand 1993
- Bronze Medal-4th INTERNATIONAL BIOLOGY OLYMPIAD-University of Utrecht 07/1993
- Honor for Excellence in Surgery - Chulalongkorn University, Bangkok, Thailand 1996 - 1997
- Honor for Excellence in Orthopedics - Chulalongkorn University, Bangkok, Thailand 1998
- Honor for Excellence in Pediatrics - Chulalongkorn University, Bangkok, Thailand 1998
- Medical Students Congress Travel Award - Ain Shams International Medical 1998
- Summa Cum Laude - Chulalongkorn University, Bangkok, Thailand 1999
- Outstanding Staff - Mongkut Rayong Hospital, Rayong, Thailand 2000
- Second place in Resident Research Competition - Physician Education Foundation, Albert Einstein Medical Center 2002 - 2003
- Sonia Stupniker, M.D. Library Award - Albert Einstein Medical Center, Philadelphia, Pennsylvania 2005  
In recognition of outstanding achievement in scholarly activity
- Lynn Sage Foundation Scholar Award - Lynn Sage Foundation, Lurie Cancer Center, Chicago, Illinois 2007
- The Physician Colleague (Attending) - Special Achievement Award - University of Maryland Medical Center For the Nursing Excellence Awards 2013

## Previous Professional Positions and Major Appointments

- Instructor - Department of Pharmacology, Chulalongkorn University 1999 - 2000
- General Practitioner - Mongkut Rayong Hospital, Rayong, Thailand 2000 - 2002
- Assistant Professor - University of Maryland School of Medicine, Baltimore, Maryland 2008 – 2014

## Professional Memberships and Services

- American Association for Cancer Research  
Active Member 2006 - Present
- Women in Cancer Research  
Associate Member 2006 - Present
- American Medical Association  
Associate 2002 - 2005



- Gonadal Hormones and Inhibitors Small Group  
Pathophysiology and Therapeutics II for Medical Students, University of Maryland School of  
Medicine Baltimore, Maryland 04/29/2009
- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of  
Medicine Baltimore, Maryland 05/01/2009
- Hormone Therapy in Breast Cancer  
Hematology/Oncology Fellows, University of Maryland School of Medicine Baltimore,  
Maryland 05/21/2009
- Breast Cancer Board Review  
Hematology/Oncology Fellows, University of Maryland School of Medicine Baltimore,  
Maryland 06/26/2009
- Systemic Adjuvant Therapy for Early Stage Breast Cancer The 7th Annual Breast Cancer  
Update, University of Maryland Baltimore, Maryland 11/06/2009
- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of  
Medicine Baltimore, Maryland 04/02/2010
- Gonadal Hormones and Inhibitors Small Group  
Pathophysiology and Therapeutics II for Medical Students, University of Maryland School of  
Medicine Baltimore, Maryland 04/30/2010
- Adjuvant Therapy in Breast Cancer  
Hematology/Oncology Fellows, University of Maryland School of Medicine Baltimore,  
Maryland 05/20/2010
- Medical Oncology Aspects of Breast Cancer  
Radiation Oncology Residents, University of Maryland School of Medicine Baltimore,  
Maryland 0 8/04/2010
- Emerging Trends in Breast Cancer 2010  
Medical Oncology Grand Round, University of Maryland Baltimore, Maryland 10/04/2010
- Chemotherapy for Stage I-III Breast Cancer  
Hematology/Oncology Fellows, University of Maryland School of Medicine Baltimore,  
Maryland 11/11/2010
- ICM II small group sessions Physical Examination for Medical Students, University of  
Maryland School of Medicine Baltimore, Maryland 2011 - 2013
- Clinical Aspects of Breast Cancer

- Advanced Cancer Biology Course for Graduate Students, University of Maryland School of Medicine Baltimore, Maryland 04/06/2011
- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of Medicine Baltimore, Maryland 04/11/2011
- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of Medicine Baltimore, Maryland 04/29/2011
- Gonadal Hormones and Inhibitors Small Group  
Pathophysiology and Therapeutics II for Medical Students, University of Maryland School of Medicine Baltimore, Maryland 05/02/2011
- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of Medicine Baltimore, Maryland 05/04/2011
- Updates in Adjuvant Therapy for Breast Cancer and Steps for Personalized Therapy  
www.umm.edu and www.umgcc.org Physician Outreach CME Program 07/28/2011
- Medical Oncology Aspects of Early Stage Breast Cancer  
Radiation Oncology Residents, University of Maryland School of Medicine Baltimore, Maryland 08/31/2011
- Breast Cancer Updates in 2011  
Medical Oncology Grand Round, University of Maryland Baltimore, Maryland 09/09/2011
- Triple Negative Breast Cancer: An Update on Novel Systemic Therapies The 9th Annual Breast Cancer Update, University of Maryland Baltimore, Maryland 11/30/2011
- Gonadal Hormones and Inhibitors Small Group  
Pathophysiology and Therapeutics II for Medical Students, University of Maryland School of Medicine Baltimore, Maryland 04/18/2012
- Adjuvant Chemotherapy for stage I-III Breast Cancer Hematology/Oncology Fellows, University of Maryland School of Medicine Baltimore, Maryland 10/18/2012
- The First Bench to Bedside Grand Rounds: Aromatase Inhibitors Internal Medicine Grand Round, University of Maryland Baltimore, Maryland 10/24/2012
- Update on Breast Cancer Clinical Trials at the University of Maryland Cancer Center The 10th Annual Breast Cancer Update, University of Maryland Baltimore, Maryland 10/26/2012
- Medical Oncology Aspects of Early Stage Breast Cancer  
Radiation Oncology Residents, University of Maryland School of Medicine Baltimore, Maryland 10/31/2012

- Clinical Aspects of Breast Cancer  
Advanced Cancer Biology Course for Graduate Students, University of Maryland School of Medicine Baltimore, Maryland 04/05/2013
- Gonadal Hormones and Inhibitors Small Group  
Pathophysiology and Therapeutics II for Medical Students, University of Maryland School of Medicine Baltimore, Maryland 04/18/2013
- Therapies for Advanced HER2-Positive Breast Cancer: Leveraging Molecular Pathways in Resistant Disease Bay Medical Center Panama, Florida 06/05/2013
- Therapies for Advanced HER2-Positive Breast Cancer: Leveraging Molecular Pathways in Resistant Disease St. Mary's Regional Cancer Center Reno, Nevada 06/07/2013
- Therapies for Advanced HER2-Positive Breast Cancer: Leveraging Molecular Pathways in Resistant Disease Clearfield Hospital Clearfield, Pennsylvania 06/13/2013

### C. Mentorship

Individual and Position	Timeframe	Outcomes	Current Status
Slovic, Jana Graduate Student	1/2008 - 1/2013 Thesis Committee member		Postdoctoral Fellow
Choe, Moran Graduate Student	1/2009 - 1/2013 Thesis Committee member	PhD Graduate	Postdoctoral Fellow
Eades, Gabriel Graduate Student	1/2010 - 1/2014 Thesis Committee member	PhD Graduate	Postdoctoral Fellow
Cheng, Emily Graduate Student	1/2011 - 1/2014 Thesis Committee member	PhD Graduate	Postdoctoral Fellow
Kazi, Armina Postdoctoral Fellow	1/2011 - 4/2017	Postdoctoral DOD award 2011	Assistant Professor, Loyola University
Reader, Jocelyn Postdoctoral Fellow	1/2012 - 1/2014 Postdoctorate Committee member		Postdoctoral Fellow
Thein, Mya	1/2012 - 8/2014	AACR/ASCO Vail Workshop 2012	Assistant Professor



## Invited

- Breast Cancer Stem Cells Endocrine Responsive Cancer Meeting Group, University of Maryland School of Medicine Baltimore, Maryland 02/02/2007
- Cancer Stem Cells in Solid Tumors 04/04/2007  
Stem Cell Meeting Group, University of Maryland School of Medicine Baltimore, Maryland
- Stem Cells and Cancer Stem Cells  
Experimental Therapeutic Meeting Group, University of Maryland School of Medicine Baltimore, Maryland 03/17/2009
- Current Investigator Initiation Trials for Breast Cancer  
Hormone Responsive Retreat, University of Maryland Baltimore, Maryland 09/25/2009
- Novel Predictive and Prognostic Biomarkers in Breast Cancer  
Upper Chesapeake Annual Breast Cancer Conference, Upper Chesapeake Hospital Bel Air, Maryland 10/10/2009
- Histone Deacetylase Targeting as a Method for Re-establishing Hormone Responsiveness in Breast Cancer 15th Annual Phase II Symposium, University of Chicago  
Chicago, Illinois 04/23/2010
- Updates from San Antonio Breast Cancer Symposium 02/11/2011  
Hormone Responsive Program Meeting, University of Maryland Baltimore, Maryland
- Clinical Aspects of Breast cancer 09/08/2011  
Nurses, Women, & Health Cultural Competence in Caring for Today's Woman Conference, University of Maryland Baltimore, Maryland
- Reprogramming breast cancer using HDAC inhibitor 11/06/2012  
Breast Cancer Program Seminar Series, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland
- What's New in the Treatment of Hormone Receptor Positive Disease 08/01/2015  
25th Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida
- Gynecologic Issues in Breast Cancer Patients 10/02/2015  
Mayo Clinic OB/GYN Clinical Reviews 2015 Orlando, Florida
- Neoadjuvant Therapy from a Medical Oncologist Perspective 11/14/2015  
Mayo Clinic Multidisciplinary Update in Breast Disease 2015 Minneapolis, MN
- What's New with Neoadjuvant and Adjuvant Endocrine Therapy 11/14/2015  
Mayo Clinic Multidisciplinary Update in Breast Disease 2015 Rochester, MN, Minnesota
- Updates on Triple Negative Breast Cancer 02/12/2016  
Mayo Clinic Advances in Breast Cancer Management 2016 Jacksonville, Florida
- Breast Cancer in Premenopausal Women 2017 02/10/2017



Mayo Clinic advances in Breast Cancer Management 2017 Jacksonville, Florida

**Research Grants Awarded**

Active Grants

**Foundation**

Co-Investigator      Genomic Analysis of ERBB2 Activity and Expression in      10/2017 - 09/2018  
HER2 Tumor Cells. Funded by Breast Cancer Research  
Foundation. (BCRF-16-159)

**Industry**

Principal              Aurora Kinase and Taxanes Resistance. Funded by      07/2007 - 06/2008  
Investigator           Amgen

Principal              A Pilot and Phase II Study of Vorinostat and Lapatinib      09/2010 - 06/2012  
Investigator           in Women with Local Recurrent or Metastatic Breast  
Cancer to Evaluate Response and Surrogate Biomarkers  
of EMT and Breast CSCs. Funded by GSK and Merck

Principal              A Pilot Phase II Study of Everolimus, Lapatinib, and      01/2012 - 04/2016  
Investigator           Letrozole in Postmenopausal Women with Advanced  
Endocrine Resistant Breast Cancer. Funded by Novartis  
and GSK

**Mayo**

Principal              Mayo Clinic Scholarly Opportunity Initiative - Phase II      10/2014 - 12/2014  
Investigator           protocol of binimetinib in combination with letrozole in  
postmenopausal women with advanced endocrine  
resistant breast cancer. . Funded by Mayo Clinic

**Other**

Principal              Mayo Clinic Cancer Focused Research Team - To      04/2015 - 12/2016  
Investigator           develop Preclinical and Phase II clinical trial of  
Carfilzomib in Triple Negative Breast Cancer.. Funded  
by Mayo Clinic

**Bibliography**

Peer-reviewed Articles

1. Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, Stass SA, Zhao XF. Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study. *Diagn Pathol.* 2007; 2:42. Epub 2007 Oct 31. PMID: 17974004 PMCID: 2186303 DOI: 10.1186/1746-1596-2-42

2. Chumsri S, Zimrin AB, Gibble JW, Hess JR. Transfusion medicine illustrated: centrolobular lung edema in probable transfusion-related acute lung injury. *Transfusion*. 2007 Feb; 47(2):183. PMID: 17302758 DOI: 10.1111/j.1537-2995.2007.01087.x
3. Chumsri S, Phatak P, Edelman MJ, Khakpour N, Hamburger AW, Burger AM. Cancer stem cells and individualized therapy. *Cancer Genomics Proteomics*. 2007 May-Jun; 4(3):165-74. PMID: 17878520
4. Chumsri S, Matsui W, Burger AM. Therapeutic implications of leukemic stem cell pathways. *Clin Cancer Res*. 2007 Nov 15; 13(22 Pt 1):6549-54. PMID: 18006753 PMCID: 2610670 DOI: 10.1158/1078-0432.CCR-07-1088
5. Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. *Clin Exp Metastasis*. 2008; 25(5):549-57. Epub 2008 Apr 02. PMID: 18386134 DOI: 10.1007/s10585-008-9169-z
6. Chumsri S, Burger AM. Cancer stem cell targeted agents: therapeutic approaches and consequences. *Curr Opin Mol Ther*. 2008 Aug; 10(4):323-33. PMID: 18683096
7. Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. *Clin Breast Cancer*. 2010 Feb; 10(1):40-5. PMID: 20133257 DOI: 10.3816/CBC.2010.n.005
8. Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. *Br J Cancer*. 2010 Mar 2; 102(5):815-26. Epub 2010 Feb 09. PMID: 20145614 PMCID: 2833247 DOI: 10.1038/sj.bjc.6605553
9. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, Chen H, Chumsri S, Burger AM, Qiu Y. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. *Genes Cancer*. 2010 Sep; 1(9):908-16. PMID: 21779471 PMCID: 3092260 DOI: 10.1177/1947601910388271
10. Brodie AMH, Chumsri S, Sukumar S, Sabnis G. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. *Hormone Molecular Biology and Clinical Investigation*. 2011; 5(2):97-103. DOI: 10.1515/HMBCI.2011.010
11. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. *Cancer Res*. 2011 Mar 1; 71(5):1893-903. Epub 2011 Jan 18. PMID: 21245100 PMCID: 3076193 DOI: 10.1158/0008-5472.CAN-10-2458
12. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. *J Steroid Biochem Mol Biol*. 2011 May; 125(1-2):13-22. Epub 2011 Feb 16. PMID: 21335088 PMCID: 3104073 DOI: 10.1016/j.jsbmb.2011.02.001
13. Chumsri S, Sabnis GJ, Howes T, Brodie AM. Aromatase inhibitors and xenograft studies. *Steroids*. 2011 Jul; 76(8):730-5. Epub 2011 Mar 21. PMID: 21420993 PMCID: 3114257 DOI: 10.1016/j.steroids.2011.02.033

14. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. *J Biol Chem*. 2011 Jul 22; 286(29):25992-6002. Epub 2011 May 19. PMID: 21596753 PMCID: 3138315 DOI: 10.1074/jbc.M111.229401

15. Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, Greco GE, Brodie AH, Tomkinson AE, Rassool FV. Targeting abnormal DNA repair in therapy-resistant breast cancers. *Mol Cancer Res*. 2012 Jan; 10(1):96-107. Epub 2011 Nov 23. PMID: 22112941 PMCID: 3319138 DOI: 10.1158/1541-7786.MCR-11-0255

16. Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk K, Feigenberg S. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1; 83(5):1387-93. Epub 2012 Jan 31. PMID: 22300561 DOI: 10.1016/j.ijrobp.2011.10.075

17. Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. *Breast Cancer Res Treat*. 2012 Oct; 135(3):681-92. Epub 2012 Aug 10. PMID: 22878889 DOI: 10.1007/s10549-012-2148-8

18. Chumsri S, Shah P. Radiation Resistance of Cancer Stem Cells as an Obstacle in Cancer Therapy. *Mol Cell Pharmacol*. 2013; 5(1):39-49. DOI: 10.4255/mcpharmacol.13.06

19. Sheth NU, Gilmore S, Bauer K, Chumsri S. The effect of atazanavir on doxorubicin pharmacokinetics: A case report. *JHOP*. 2013; 3(2):1.

20. Bao T, Cai L, Giles JT, Gould J, Tarpinian K, Betts K, Medeiros M, Jeter S, Tait N, Chumsri S, Armstrong DK, Tan M, Folklerd E, Dowsett M, Singh H, Tkaczuk K, Stearns V. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. *Breast Cancer Res Treat*. 2013 Feb; 138(1):167-74. Epub 2013 Feb 08. PMID: 23393007 PMCID: 3594526 DOI: 10.1007/s10549-013-2427-z

21. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, Regine WF, Feigenberg SJ. Increasing national mastectomy rates for the treatment of early stage breast cancer. *Ann Surg Oncol*. 2013 May; 20(5):1436-43. Epub 2012 Nov 08. PMID: 23135312 DOI: 10.1245/s10434-012-2732-5

22. Bhatnagar B, Gilmore S, Goloubeva O, Pelsner C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. *Springerplus*. 2014; 3:366. PMID: 25089251 PMCID: 4117856 DOI: 10.1186/2193-1801-3-366

23. Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. *Curr Pharm Des*. 2014; 20(42):6575-83. PMID: 25341934

24. Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. *Breast Cancer Res*. 2014; 16(1):R15. Epub 2014 Jan 29. PMID: 24472707 PMCID: 3978891 DOI: 10.1186/bcr3609

25. Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, Li S, Amstutz P, Tang CM. The systematic study of circulating tumor cell isolation using lithographic microfilters. *RSC Adv.* 2014; 9:4334- 4342. PMID: 25614802 PMCID: 4299665 DOI: 10.1039/C3RA46839A
26. Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. *Future Oncol.* 2014 Feb; 10: (3)443-56. PMID: 24559450 DOI: 10.2217/fon.13.178
27. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KH, Stearns V. Patient-reported outcomes in women with breast cancer enrolled in a dual- center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. *Cancer.* 2014 Feb 01; 120: (3)381-9. PMID: 24375332 PMCID: 3946917 DOI: 10.1002/cncr.28352
28. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. *Proc Natl Acad Sci U S A.* 2014 Mar 04; 111: (9)3514-9. PMID: 24550495 PMCID: 3948254 DOI: 10.1073/pnas.1320198111
29. Chumsri S, Schech A, Chakkabat C, Sabnis G, Brodie A. Advances in mechanisms of resistance to aromatase inhibitors. *Expert Rev Anticancer Ther.* 2014 Apr; 14: (4)381-93. PMID: 24559291 DOI: 10.1586/14737140.2014.882233
30. Singh SN, Zhu Y, Chumsri S, Kesmodel S, Gilliam BL, Riedel DJ. Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer. *Clin Breast Cancer.* 2014 Apr; 14: (2)e53-9. PMID: 24418743 PMCID: 3960406 DOI: 10.1016/j.clbc.2013.11.002
31. Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H. Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, alpha9 nicotinic acetylcholine receptor and STAT3. *Breast Cancer Res Treat.* 2014 May; 145: (1)5-22. PMID: 24668500 PMCID: 4028025 DOI: 10.1007/s10549- 014-2912-z
32. Suzuki I, Chakkabat P, Goicochea L, Campassi C, Chumsri S. Lymphoepithelioma-like carcinoma of the breast presenting as breast abscess. *World J Clin Oncol.* 2014 Dec 10; 5: (5)1107-12. PMID: 25493247 PMCID: 4259938 DOI: 10.5306/wjco.v5.i5.1107
33. Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer. *Int J Womens Health.* 2015; 7:493-9. PMID: 26005359 PMCID: 4427607 DOI: 10.2147/IJWH.S69907
34. Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch(R) CTC test. *Cytometry Part A.* 2015; 87(2):137-44.
35. Advani P, Cornell L, Chumsri S, Moreno-Aspitia A. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. *Breast Cancer (Dove Med Press).* 2015; 7:321-35. PMID: 26451122 PMCID: 4590321 DOI: 10.2147/BCTT.S90627
36. Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S. Brain metastasis and response to ado- trastuzumab emtansine: a case report and literature review. *Clin Breast Cancer.* 2015 Apr; 15: (2)e163-6. PMID: 25454740 DOI: 10.1016/j.clbc.2014.10.003

37.Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates her2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. *Breast Cancer Res Treat.* 2015 Aug; 152(3):499-508. PMID: 26133921

38.Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, Chenna A, Huang W, DeRidder A, Goicocheal L, Perez EA. Prolonged Response to Trastuzumab in a Patient With HER2- Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. *J Natl Compr Canc Netw.* 2015 Sep; 13: (9)1066-70. PMID: 26358791

39.Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell AD Jr, Sudol M, Passaniti A. RUNX2 and TAZ- dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. *Oncotarget.* 2015 Sep 29; 6: (29)28132-50. PMID: 26320173 PMCID: 4695049 DOI: 10.18632/oncotarget.4654

40.Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A. The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. *J Cell Biochem.* 2015 Oct; 116: (10)2210-26. PMID: 25808624 PMCID: 4885214 DOI: 10.1002/jcb.25171

41.Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S, Tang CM, Stefansson S. Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. *RSC Adv.* 2016; 6 (8):6405-6414 Epub 2016 Jan 11 PMID: 29093811 PMCID: 5662211 DOI: 10.1039/c5ra21524b

42.Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, Ordentlich P, Trepel JB. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of encore 301, a randomized, placebo-controlled phase ii trial of exemestane with or without entinostat *Oncoimmunology.* 2016; 5: (11)e1219008.

43.Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. *Breast Cancer Res.* 2016 May 04; 18: (1)44. PMID: 27142282 PMCID: 4855427 DOI: 10.1186/s13058-016-0706-4

44.Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors. *Am J Clin Oncol.* 2016 Jun 17; PMID: 27322700 DOI: 10.1097/COC.0000000000000314

45.Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. *Cancer Epidemiol Biomarkers Prev.* 2016 Jul; 25 (7):1037-42 Epub 2016 May 17 PMID: 27197300 PMCID: 4930681 DOI: 10.1158/1055-9965.EPI-15-1221

46.Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. *Cancer.* 2016 Sep 01; 122: (17)2654-62. PMID: 27284958 DOI: 10.1002/cncr.30102

47. Soyano AE, Reynolds G, Moreno-Aspitia A, Chumsri S. Rifaximin for Pertuzumab-Related GI Toxicities. *Front Oncol.* 2017; 7:168 Epub 2017 Aug 08 PMID: 28848707 PMCID: 5550690 DOI: 10.3389/fonc.2017.00168

### Book Chapters

1. Chumsri S, Burger AM. Cancer stem cells. In: Columbus F. *Cancer Research Journal* 2008 Vol. 2. Nova Science Publishers, Inc.; 2008.
2. Chumsri S, Matsui W, Burger AM. Leukemic stem cell pathways - therapeutic implications. In: Bernstein L, Chairperson. 2008 AACR Educational Book San Diego, CA. Philadelphia, PA: AACR; 2008.
3. Chumsri S, Bao T, Sabnis G, Brodie A. Advances with Aromatase Inhibitors. In: Jordan VC. *Estrogen Action, SERMS and Women's Health.* Singapore: Imperial College Press; 2011. p. 201-228.
4. Chumsri S, Yu S, Schech A, Sabnis G, Brodie A. Aromatase inhibitors for breast cancer prevention. In: *Trends in breast cancer prevention.* 2016. p. 103-11.

### Letters

1. Chumsri S, Tummala MK, Khna AM, Zhao XF, Rapoport AP. Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma. *Leuk Lymphoma.* 2007 Mar; 48(3):616-8. PMID:17454607 DOI:10.1080/10428190601140058
2. Chumsri S, Zhao M, Garofalo M, Burger A, Hamburger A, Zhao F, Rapoport A. Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. *Leuk Lymphoma.* 2008 Feb; 49(2):359-61. PMID:18231928 DOI:10.1080/10428190701809214
3. Zimrin A, Chumsri S. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim. *Ann Hematol.* 2013 Aug; 92(8):1145-6. Epub 2013 Jan 18. PMID:23328792 DOI:10.1007/s00277-013-1677-5

### Abstracts

1. Chumsri S, Pavarode A, Voavud N. Survival and modalities of treatments in ruptured hepatoma. *Programs & Abstracts of the 5th Annual International Ain Shams Medical Students' Congress.* 1997 Jan:57.
2. Chumsri S, Sivak S. The value of blood cultures in community acquired pneumonia. *Ann Emerg Med.* 2003; 42(4):S36.
3. Chumsri S, Nakanishi T, Natarajan K, Phatak P, Hamburger AW, Ross DD, Burger AM. Overexpression of HER2/neu in breast cancer cell lines is associated with an increased side population, presence of ABC transporters, and clonogenicity. *Targeted Oncology.* 2007; 2:S26.

4. Chumsri S, Nakanishi T, Phatak P, Macedo LF, Sabnis G, Hamburger AW, Brodie AH, Burger AM. The overexpression of ERBB receptor tyrosine kinases and ABC transporters is associated with an increased side population in hormone resistant breast cancer cells. *Breast Cancer Research and Treatment* 3095. 2007; 106S1:S1.
5. Chumsri S, Nakanishi T, Natarajan K, Phatak P, Hamburger AW, Ross DD, Burger AM. Overexpression of HER2/neu in breast cancer cell lines is associated with an increased side population, presence of ABC transporters, and clonogenicity. *AACR Meeting Abstracts*. 2007 Apr:1278.
6. Chumsri S, Jeter SC, Jacobs LK, Lange JR, Davidson NE, Emens L, Fetting JH, Gabrielson E, Zhang Z, Stearns V. Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer. *J Clin Oncol (Meeting Abstracts)*. 2008; 26:608s.
7. Chumsri S, Nakanishi T, Phatak P, Leyland-Jones B, Ross DD, Khakpour N, Hamburger AW, Burger AM. Inhibition of HER2 and HER3 phosphorylation can diminish tumor propagating breast cancer cells in vitro and prevent tumor repopulation in NOD/SCID mice. *AACR Meeting Abstracts*. 2008 Apr:4604.
8. Weinstock C, Zhu Y, Bao T, Buras RR, Hanna NN, Tkaczuk K, Chumsri S. Relationship between Vitamin D Deficiency and Breast Cancer Histology: A Retrospective Database Review. *Cancer Res (Meeting Abstracts)*. 2009:6-06-01.
9. Passaniti T, Chumsri S, Girnun G, Brodie A, Choe M. The Warburg effect and RUNX2-regulated metabolic switching in breast cancer: A new therapeutic target? *Cancer Res (Meeting Abstracts)*. 2009:4-03-05.
10. Gilani R, Chumsri S, Sabnis G, Brodie A. All-trans retinoic acid in combination with trastuzumab can induce differentiation and diminish breast cancer stem cells in endocrine resistant breast cancer. *AACR Meeting Abstracts*. 2009 Apr:1062.
11. Tkaczuk KH, Tait NS, Ioffe O, Tan M, Mohiuddin M, Chumsri S, VanECHO DA, Sutula MJ, Lesko S, Deamond S, Ts'o P. Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). 2009 ASCO Annual Meeting. 2009 Jun:1119.
12. Chumsri S, Sabnis G, Howes, T, Brodie A. Aromatase inhibitors and xenograft studies. *Aromatase Proceeding*. 2010.
13. Linn D, Yang X, Sun F, Xie Y, Chumsri S, Burger A, Qiu Y. A functional role of OCT4 for prostate tumor initiation. *AACR Meeting Abstracts*. 2010 Apr:391.
14. Choe M, Chumsri S, Girnun G, Passaniti. Regulation of breast cancer metabolism and glycolysis by RUNX2. *Cancer Biology Research Retreat*. 2010 May.
15. Singh SN, Baer MR, Tkaczuk KH, Chumsri S, Bao T, Riedel D. Breast cancer in patients with HIV: A single-institution experience with a non-AIDS defining cancer. *J Clin Oncol*. 2011; 29(suppl):abstr e11108.

16. Mahmood U, Morris CG, Neuner GA, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk KH, Feigenberg SJ. Comparing survival with breast-conservation therapy or mastectomy in the management of young women with early-stage breast cancer. *J Clin Oncol.* 2011; 29(suppl 27):abstr 85.
17. Mahmood UA, Hanlon L, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston S, Regine W, Feigenberg SJ. Early evidence of increasing national mastectomy rates for the treatment of breast cancer. *J Clin Oncol.* 2011; 29(suppl 27):abstr 136.
18. Kazi A, Gilani R, Chumsri S, Brodie A. The potential role of nonhypoxic HIF-1 in HER2 mediated aromatase inhibitor resistant breast cancer. *AACR Meeting Abstracts.* 2011 Apr:2295.
19. Bao T, Tarpinian K, Medeiros M, Gould J, Jeter S, Cai L, Tait NS, Shetty J, Lewis JC, Gittens L, Betts K, Hoffman A, Feigenberg SJ, Chumsri S, Giles J, Armstrong D, Bardia A, Tan M, Stebbing J, Folkard E, Dowsett M, Singh H, Tkaczuk KH, Stearns V. A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Analysis. *San Antonio Breast Cancer Symposium.* 2011 Dec.
20. Chumsri S, Tait NS, Medeiros M, Bauer KS, Betts KT, Lewis JC, Bao T, Feigenberg S, Kesmodel S, Stearns V, Edelman MJ, Sausville E, Tkaczuk KH. The safety and tolerability of vorinostat in combination with lapatinib in advanced solid tumors. *San Antonio Breast Cancer Symposium.* 2011 Dec.
21. Gilani R, Kazi A, Scheh A, Chumsri S, Shah P, Brodie A. Involvement of HER2, HIF-1, and BCRP in cancer stem cell characteristics of letrozole-resistant breast cancer cells. *AACR Meeting Abstracts.* 2012 Apr:787.
22. Bhargava R, Zhu Y, Weinstock C, Hanna N, Tkaczuk K, Bao T, Chumsri S. Association between Vitamin D deficiency and breast cancer histology: a retrospective database review. *American Society of Clinical Oncology.* 2012 Jun.
23. Bao T, Betts K, Tarpinian K, Cai L, Gould J, Jeter S, Medeiros M, Tait N, Chumsri S, Armstrong D, Bardia A, Tan M, Stebbing J, Kelleher W, Folkard E, Dowsett M, Singh H, Snyder C, Tkaczuk K, Stearns V. Changes in Patient Reported Outcomes in Women with Breast Cancer in A Multi-Center Double Blind Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-induced Musculoskeletal Symptoms (AIMSS). *American Society of Clinical Oncology.* 2012 June.
24. Weinstock C, Campassi C, Goloubeva O, Chumsri S, Bao T, Kesmodel S, Feigenberg S, Wooten K, Ioffe O, Tkaczuk K. The effect on detection rate of second cancers after the addition of MRI to conventional screening mammography in patients with a history of breast cancer. *American Society of Clinical Oncology.* 2012 June.
25. Tkaczuk KHR, Cao Q, Jones L, Smith M, Chumsri S, Jenkins J, Dilsizian V, Chen W. Brown fat (BAT) seen on FDG PET/CT is increased in Breast Cancer patients (BC) compared to their age- and weight-matched controls with other cancers. *European Society for Medical Oncology.* 2012 Oct.



26. Heiss B, Thompson J, Nightingale G, Tait N, Kesmodel S, Bellavance E, Chumsri S, Bao T, Goloubeva O, Feigenberg S, Tkaczuk K. A Pilot Prospective Study of Adherence to Aromatase Inhibitor Adjuvant Therapy in Patients with Stage 1-3 Breast Carcinoma. San Antonio Breast Cancer Symposium. 2012 Dec:2-13-05.
27. Sabnis GJ, Kazi A, Goloubeva O, Chumsri S, Brodie A. HDAC inhibitor entinostat reverses letrozole resistance in MCF-7Ca xenografts through modulation of Her-2. AACR Annual Meeting. 2013:Abst 1314.
28. Adams D, Alpaugh RK, Cristofanilli M, Martin S, Chumsri S, Charpentier M, Bergan RC, Ogden IM, Tsai S, Zhu P, Makarova OV, Li S, Amstutz PT, Tang CM. Identifying and subtyping circulating tumor cells from breast, prostate, and pancreatic cancer patients based on distinct morphology. AACR Annual Meeting. 2013:Abst 1448.
29. Kazi AA, Shah P, Schech A, Sabnis G, Chumsri S, Brodie A. Inhibition of non-hypoxic HIF-1 expression in letrozole-resistant breast cancer cells reduces their cancer stem cell characteristics. AACR Annual Meeting. 2013:Abst 95.
30. Shah P, Sabnis GJ, Goloubeva O, Kazi A, Schech A, Gilani R, Gau Y, Chumsri S, Brodie A. Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. AACR Annual Meeting. 2013:Abst 1311.
31. Rosenblatt R, Singh SN, Goicochea L, Kesmodel S, Ioffe OB, Chumsri S, Riedel D. Presentation and pathology of breast cancer in patients with HIV. Breast Cancer Symposium. 2013.
32. Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. *Curr Pharm Des.* 2014;
33. Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, Li S, Amstutz P, Tang CM. The systematic study of circulating tumor cell isolation using lithographic microfilters. *RSC Adv.* 2014;
34. Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. *Future Oncol.* 2014;10(3):443-56.
35. Chumsri S, Schech A, Chakkabat C, Sabnis G, Brodie A. Advances in mechanisms of resistance to aromatase inhibitors. *Expert Rev Anticancer Ther.* 10.1586/14737140.2014.882233.2014;14(4):381-93.
36. Guha P1, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H. Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, a9 nicotinic acetylcholine receptor and STAT3. *Breast Cancer Res Treat.* 2014;
37. Bhatnagar B1, Gilmore S2, Goloubeva O3, Pelsler C1, Medeiros M1, Chumsri S1, Tkaczuk K1, Edelman M1, Bao T1. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. *Springerplus.* 2014;
38. Suzuki I, Chakkabat P, Goicochea L, Campassi C, Chumsri S. Lymphoepithelioma-like carcinoma of the breast presenting as breast abscess. *World J Clin Oncol.* 2014;

39. Rosenblatt P, Goloubeva OG, Kesmodel S, Bellavance EC, Chumsri S, Bao T, Heiss B, Nichols EM, Feigenberg SJ, Tait N, Tkaczuk KH. Adjuvant aromatase inhibitor adherence based on the morisky medication adherence scale and identification of predictors to adherence. *J Clin Oncol.* 2015 May 20; 33(15).
40. Adams DL, Martin SS, Chumsri S, Charpentier M, Alpaugh RK, Cristofanilli M, Tang CM, Haudenschild CC. Applying a mitotic index to circulating tumor cells and its prognostic significance: a cytological approach to patient stratification. *J Clin Oncol.* 2015 May 20; 33(15).
41. Adams DL, Bergan RC, Martin SS, Chumsri S, Charpentier M, Lapidus RG, Alpaugh RK, Cristofanilli M, Tsai S, Tang CM, Edelman MJ. Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies. *J Clin Oncol.* 2015 May 20; 33(15).
42. Adams D, Alpaugh K, Cristofanilli M, Martin S, Chumsri S, Bergen RC, Tsai SS, Edelman M, Zhu PX, Li SH, Makarova OV, Amstutz PT, Tang CM, Marks JR. Cancer associated macrophage-like cells as a blood-based biomarker for the screening of solid tumors *Cancer Research.* 2015 Aug 1; 75:
43. Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A. The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. *J Cell Biochem.* 2015;
44. Ordentlich P, Lee MJ, Tomita Y, Lee S, Tomita S, Cruickshank S, Chumsri S, Trepel JB. Epigenetic immune modulation by entinostat in breast cancer: correlative analysis of encore 301 trial *Cancer Immunology Research.* 2016 Jan; 4: (1).
45. Ali SM, Wang K, Johnson A, Rodriguez AA, Elvin JA, Vergilio JA, Suh JH, Chumsri S, Morosini D, Yelensky R, Lipson D, Chmielecki J, Miller VA, Ross JS, Chang J, Stephens PJ. Egfr genomic alterations in 5,605 cases of refractory and metastatic breast cancer *Cancer Research.* 2016 Feb 15; 76: (Suppl 4).
46. Chumsri S, Lee MJ, Tomita Y, Lee S, Tomita S, Cruickshank S, Ordentlich P, Trepel JB. Epigenetic immune modulation by entinostat in breast cancer: correlative analysis of encore 301 trial *Cancer Research.* 2016 Feb 15; 76:
47. Chumsri S, Necela BM, Ordentlich P, Advani P, Moreno-Aspitia A, McLaughlin SA, Geiger X, McDonough M, Vallow LA, Perez EA, Thompson EA. Immunomodulatory effects of entinostat on pd-11 and mhc class i and ii in different subtypes of breast cancer *Cancer Research.* 2016 Feb 15; 76:
48. Ross JS, Wang K, Ali SM, Chumsri S, Elvin JA, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Miller VA, Stephens PJ. Non-amplification erbb2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: an emerging opportunity for anti-her2 targeted therapies *Cancer Research.* 2016 Feb 15; 76:
49. Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors. *Am J Clin Oncol.* 2016;
50. Chumsri S, Serie DJ, Mashadi-Hosseini A, Tenner KS, Lattia SL, Moreno-Aspitia A, McLaughlin SA, Nassar A, Warren S, Danaher P, Colon-Otero G, Lindman H, Joensuu H, Perez EA, Thompson EA. Prognostic value of molecular tumor infiltrating lymphocyte (mtil) signatures in her2-

positive breast cancer patients in n9831 and finher/finxx trials Cancer Research. 2017 Feb; 77: (Suppl 4)PD5-06.

### **Forthcoming**

1. Chumsri S, Schech A, Tait N, Lewis J, Bao T, Tkaczuk K, Stearns V, Edelman MJ, Brodie A. Targeting cancer stem cells and metastasis with epigenetic modulation and anti-HER2 therapy: Phase I/II trial of vorinostat in combination with lapatinib. In Press